Statin initiation and risk of incident kidney disease in patients with diabetes.

Abstract

BACKGROUND:

The role of statin therapy in the development of kidney disease in patients with type 2 diabetes mellitus (DM) remains uncertain. We aimed to determine the relationships between statin initiation and kidney outcomes in patients with type 2 DM.

METHODS:

Through a new-user design, we conducted a multicentre retrospective cohort study using the China Renal Data System database (which includes inpatient and outpatient data from 19 urban academic centres across China). We included patients with type 2 DM who were aged 40 years or older and admitted to hospital between Jan. 1, 2000, and May 26, 2021, and excluded those with pre-existing chronic kidney disease and those who were already on statins or without follow-up at an affiliated outpatient clinic within 90 days after discharge. The primary exposure was initiation of a statin. The primary outcome was the development of diabetic kidney disease (DKD), defined as a composite of the occurrence of kidney dysfunction (estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73 m2 and > 25% decline from baseline) and proteinuria (a urinary albumin-to-creatinine ratio ≥ 30 mg/g and > 50% increase from baseline), sustained for at least 90 days; secondary outcomes included development of kidney function decline (a sustained > 40% decline in eGFR). We used Cox proportional hazards regression to evaluate the relationships between statin initiation and kidney outcomes, as well as to conduct subgroup analyses according to patient characteristics, presence or absence of dyslipidemia, and pattern of dyslipidemia. For statin initiators, we explored the association between different levels of lipid control and outcomes. We conducted analyses using propensity overlap weighting to balance the participant characteristics.

RESULTS:

Among 7272 statin initiators and 12 586 noninitiators in the weighted cohort, statin initiation was associated with lower risks of incident DKD (hazard ratio [HR] 0.72, 95% confidence interval [CI] 0.62-0.83) and kidney function decline (HR 0.60, 95% CI 0.44-0.81). We obtained similar results to the primary analyses for participants with differing patterns of dyslipidemia, those prescribed different statins, and after stratification according to participant characteristics. Among statin initiators, those with intensive control of high-density lipoprotein cholesterol (LDL-C) (< 1.8 mmol/L) had a lower risk of incident DKD (HR 0.51, 95% CI 0.32-0.81) than those with inadequate lipid control (LDL-C ≥ 3.4 mmol/L).

INTERPRETATION:

For patients with type 2 DM admitted to and followed up in academic centres, statin initiation was associated with a lower risk of kidney disease development, particularly in those with intensive control of LDL-C. These findings suggest that statin initiation may be an effective and reasonable approach for preventing kidney disease in patients with type 2 DM.

• Authors: Shiyu Zhou, Licong Su, Ruqi Xu, Yanqin Li, Ruixuan Chen, Yue Cao, Peiyan Gao, Xiaodong Zhang, Fan Luo, Qi Gao, Shengli An, Wenyi Cai, Lilong Lin, Hong Xu, Bicheng Liu, Jianping Weng, Chen Chunbo, Huafeng Liu, Qiongqiong Yang, Hua Li, Yaozhong Kong, Guisen Li, Qijun Wan, Yan Zha, Ying Hu, Gang Xu, Yongjun Shi, Yilun Zhou, Guobin Su, Ying Tang, Mengchun Gong, Xin Xu, Sheng Nie
• Journal: CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne (CMAJ) Vol. 195 Issue 21 Pg. E729-E738 (05 29 2023) ISSN: 1488-2329 [Electronic] Canada
• PMID: 37247880 (Publication Type: Journal Article)
• Copyright: © 2023 CMA Impact Inc. or its licensors.

Chemical References

• Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Cholesterol, LDL

Topics

• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (adverse effects)
• Diabetes Mellitus, Type 2 (drug therapy, epidemiology)
• Cholesterol, LDL
• Retrospective Studies
• Renal Insufficiency, Chronic (epidemiology)
• Dyslipidemias (drug therapy, epidemiology)